Press "Enter" to skip to content

Tag: nirmatrelvir

Topic: PaxlovidView all posts for the topic: Paxlovid

Paxlovid cuts COVID hospitalization, death risk and speeds symptom relief, studies find

Published November 11, 2024

Still COVIDing Canada Posts

Published by: CIDRAP
Published on:
By Mary Van Beusekom

New findings from two studies have tied use of the antiviral drug nirmatrelvir-ritonavir (Paxlovid) to a reduction in COVID-19 hospitalizations and death, as well as to faster resolution of symptoms and less use of healthcare resources.

Continue readingPaxlovid cuts COVID hospitalization, death risk and speeds symptom relief, studies find
Comments closed
Topic: PaxlovidView all posts for the topic: Paxlovid

Paxlovid tied to fewer COVID-19 hospitalizations, reduced risk of long COVID

Published October 29, 2024

Still COVIDing Canada Posts

Published by: CIDRAP
Published on:
By Stephanie Soucheray

A new retrospective cohort study conducted in Dubai shows that the antiviral nirmatrelvir plus ritonavir, sold as Paxlovid, is tied to a 61% reduction in COVID-19 hospitalization and a 58% lower rate of long COVID.

Continue readingPaxlovid tied to fewer COVID-19 hospitalizations, reduced risk of long COVID
Comments closed